Verition Fund Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.7M | Buy |
14,719
+11,166
| +314% | +$2.4M | 0.02% | 797 |
|
|
2026
Q1 | $773K | Sell |
3,553
-31,852
| -90% | -$7.07M | 0.01% | 1413 |
|
|
2025
Q4 | $8.09M | Buy |
35,405
+17,963
| +103% | +$4.09M | 0.03% | 570 |
|
|
2025
Q3 | $4.04M | Sell |
17,442
-56,215
| -76% | -$11.4M | 0.02% | 1368 |
|
|
2025
Q2 | $13.7M | Buy |
73,657
+53,080
| +258% | +$9.86M | 0.06% | 373 |
|
|
2025
Q1 | $4.31M | Buy |
20,577
+14,605
| +245% | +$2.84M | 0.02% | 954 |
|
|
2024
Q4 | $1.06M | Buy |
5,972
+2,506
| +72% | +$461K | ﹤0.01% | 2007 |
|
|
2024
Q3 | $684K | Sell |
3,466
-16,142
| -82% | -$3.01M | ﹤0.01% | 2127 |
|
|
2024
Q2 | $3.36M | Buy |
19,608
+6,098
| +45% | +$1.01M | 0.02% | 969 |
|
|
2024
Q1 | $2.46M | Sell |
13,510
-1,023
| -7% | -$176K | 0.02% | 1093 |
|
|
2023
Q4 | $2.25M | Buy |
14,533
+2,133
| +17% | +$311K | 0.02% | 781 |
|
|
2023
Q3 | $1.85M | Sell |
12,400
-14,283
| -54% | -$2.1M | 0.02% | 824 |
|
|
2023
Q2 | $3.6M | Buy |
+26,683
| New | +$3.91M | 0.05% | 452 |
|
|
2023
Q1 | – | Sell |
-5,915
| Closed | -$956K | – | 2117 |
|
|
2022
Q4 | $956K | Sell |
5,915
-3,333
| -36% | -$511K | 0.01% | 927 |
|
|
2022
Q3 | $1.24M | Buy |
9,248
+7,921
| +597% | +$1.14M | 0.01% | 1246 |
|
|
2022
Q2 | $203K | Buy |
+1,327
| New | +$203K | ﹤0.01% | 1940 |
|
|
2021
Q4 | – | Sell |
-3,109
| Closed | -$367K | – | 2505 |
|
|
2021
Q3 | $335K | Sell |
3,109
-2,357
| -43% | -$269K | ﹤0.01% | 1421 |
|
|
2021
Q2 | $616K | Buy |
+5,466
| New | +$616K | 0.01% | 1001 |
|
|
2020
Q4 | – | Sell |
-8,524
| Closed | -$819K | – | 1059 |
|
|
2020
Q3 | $747K | Buy |
8,524
+3,252
| +62% | +$306K | 0.01% | 448 |
|
|
2020
Q2 | $518K | Sell |
5,272
-209,728
| -98% | -$18.5M | 0.02% | 594 |
|
|
2020
Q1 | $16.4M | Buy |
215,000
+206,069
| +2,307% | +$17.6M | 0.65% | 39 |
|
|
2019
Q4 | $791K | Buy |
+8,931
| New | +$741K | 0.01% | 512 |
|
|
2019
Q3 | – | Sell |
-29,628
| Closed | -$2.03M | – | 1014 |
|
|
2019
Q2 | $2.15M | Buy |
29,628
+13,149
| +80% | +$1.03M | 0.06% | 224 |
|
|
2019
Q1 | $1.33M | Buy |
+16,479
| New | +$1.35M | 0.05% | 314 |
|
|
2018
Q4 | – | Sell |
-4,104
| Closed | -$388K | – | 788 |
|
|
2018
Q3 | $388K | Sell |
4,104
-5,522
| -57% | -$524K | 0.01% | 936 |
|
|
2018
Q2 | $892K | Buy |
9,626
+2,357
| +32% | +$230K | 0.05% | 457 |
|
|
2018
Q1 | $688K | Buy |
7,269
+500
| +7% | +$54.9K | 0.05% | 507 |
|
|
2017
Q4 | $655K | Buy |
+6,769
| New | +$638K | 0.06% | 393 |
|
|
2016
Q4 | – | Sell |
-3,534
| Closed | -$223K | – | 1138 |
|
|
2016
Q3 | $223K | Buy |
+3,534
| New | +$229K | 0.02% | 938 |
|
|
2016
Q2 | – | Sell |
-21,568
| Closed | -$1.23M | – | 860 |
|
|
2016
Q1 | $1.23M | Buy |
21,568
+16,131
| +297% | +$899K | 0.2% | 107 |
|
|
2015
Q4 | $322K | Buy |
+5,437
| New | +$313K | 0.06% | 283 |
|
|
2015
Q1 | – | Sell |
-4,082
| Closed | -$267K | – | 378 |
|
|
2014
Q4 | $267K | Buy |
+4,082
| New | +$257K | 0.06% | 165 |
|
|
2014
Q3 | – | Sell |
-6,509
| Closed | -$367K | – | 695 |
|
|
2014
Q2 | $367K | Buy |
+6,509
| New | +$341K | 0.04% | 351 |
|
|
2014
Q1 | – | Sell |
-8,695
| Closed | -$459K | – | 484 |
|
|
2013
Q4 | $459K | Buy |
8,695
+2,361
| +37% | +$116K | 0.08% | 194 |
|
|
2013
Q3 | $283K | Sell |
6,334
-14,695
| -70% | -$651K | 0.04% | 352 |
|
|
2013
Q2 | $869K | Buy |
+21,029
| New | +$920K | 0.16% | 124 |
|
Other funds holding ABBV
Verition Fund Management's ABBV Position: Q2 2026 in Review
Verition Fund Management increased its AbbVie (ABBV) stake by 314% in Q2 2026, buying an estimated $2.4M and bringing the position to 14,719 shares worth $3.7M. The position accounts for 0.02% of the portfolio, ranked #797.
Verition Fund Management first reported a position in ABBV in Q2 2013 and has held it in 36 quarters since. The position peaked at $16.4M in Q1 2020. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Verition Fund Management held 14,719 shares of AbbVie worth $3.7M as of Q2 2026.
- Verition Fund Management bought 11,166 AbbVie shares in Q2 2026, an estimated $2.4M.
- AbbVie made up 0.02% of Verition Fund Management's portfolio in Q2 2026, its #797 holding.
- Verition Fund Management first reported a position in AbbVie in Q2 2013 and has held it in 36 quarters since.
- Verition Fund Management's AbbVie position peaked at $16.4M in Q1 2020.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.